SUN Pharmaceutical Industries Limited — Sitagliptin Exporter Profile
Indian Pharmaceutical Exporter · #12 for Sitagliptin · $2.0M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #12 Indian exporter of Sitagliptin with $2.0M in export value and 82 verified shipments. SUN Pharmaceutical Industries Limited holds a 2.7% market share in Sitagliptin exports across 7 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Sitagliptin Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Sitagliptin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $1.1M | 60 | 63.8% |
| BELGIUM | $292.6K | 10 | 17.7% |
| AUSTRALIA | $190.0K | 5 | 11.5% |
| CANADA | $44.5K | 2 | 2.7% |
| MALAYSIA | $43.3K | 2 | 2.6% |
| PERU | $27.9K | 2 | 1.7% |
| ROMANIA | $54 | 1 | 0.0% |
SUN Pharmaceutical Industries Limited exports Sitagliptin to 7 countries. The largest destination is BRAZIL accounting for 63.8% of SUN Pharmaceutical Industries Limited's Sitagliptin shipments, followed by BELGIUM (17.7%) and AUSTRALIA (11.5%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Sitagliptin from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| RANBAXY FARMACEUTICA LTDA : | BRAZIL | $383.6K | 13 |
| RANBAXY FARMACEUTICA LTDA | BRAZIL | $306.7K | 16 |
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $242.6K | 9 |
| RANBAXY FARMACEUTICA LTDA: | BRAZIL | $228.9K | 8 |
| SUN PHARMA ANZ PTY LTD. | AUSTRALIA | $190.0K | 5 |
| RANBAXY FARMACEUTICA LIMITED | BRAZIL | $96.7K | 3 |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | BELGIUM | $50.0K | 1 |
| TARO PHARMACEUTICALS INC., | CANADA | $44.5K | 2 |
| RANBAXY(MALAYSIA)SDN.BHD. | MALAYSIA | $43.3K | 2 |
| M/S. RANBAXY FARMACEUTICA LTDA : | BRAZIL | $30.6K | 1 |
SUN Pharmaceutical Industries Limited supplies Sitagliptin to 15 buyers globally. The largest buyer is RANBAXY FARMACEUTICA LTDA : (BRAZIL), followed by RANBAXY FARMACEUTICA LTDA (BRAZIL) and YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Sitagliptin Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $46.1M worth of Sitagliptin through 5,364 shipments from 309 suppliers to 121 countries, serving 575 buyers globally. SUN Pharmaceutical Industries Limited contributes $2.0M to this total, accounting for 2.7% of India's Sitagliptin exports. SUN Pharmaceutical Industries Limited ships Sitagliptin to 7 countries through 15 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Sitagliptin Exports?
SUN Pharmaceutical Industries Limited's average Sitagliptin shipment value is $24.7K per consignment, based on 82 shipments totaling $2.0M. The largest destination is BRAZIL (63.8% of SUN Pharmaceutical Industries Limited's Sitagliptin exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Sitagliptin Exporters?
SUN Pharmaceutical Industries Limited ranks #12 among 309 Indian Sitagliptin exporters with a 2.7% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($7.7M), MYLAN LABORATORIES LIMITED ($7.0M), SANDOZ PRIVATE LIMITED ($6.5M). SUN Pharmaceutical Industries Limited processed 82 shipments to 7 destination countries.
What Sitagliptin Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| FOST DE SITAGLIPTINA TAB 100MG 3X10B BREACH CONTAINS: SITAGLIPTINA PHOSPHATE TABLETS PACK : BOX3X10S | $207.1K | 6 |
| FOST DE SITAGLIPITINA TAB 100MG 3X10B BREACH CONTAINS: SITAGLIPTINA PHOSPHATE TABLETS. PACK: BOX3X10S | $138.1K | 3 |
| FOST DE SITAGLIPTINA TABLETS 50MG (EACHTABLETS CONTAINS: SITAGLIPTIN PHOSPHATE50MG) [39358 PACKS X3X10'S] (BATCH NO. P | $90.2K | 3 |
| FOST DE SITAGLIPTINA TABLETS 100MG (EACHTABLETS CONTAINS: SITAGLIPTIN PHOSPHATE100MG) [13800 PACKS X3X10'S] (BATCH NO. | $73.7K | 3 |
| FOST DE SITAGLIPTINA TABLETS 50MG (EACHTABLETS CONTAINS: SITAGLIPTIN PHOSPHATETABLETS 50MG) [24080 PACKS X3X10'S] B NO | $55.0K | 3 |
| FOST DE SITAGLIPTINA TAB 50MG 3X10B BR EACH CONTAINS: SITAGLIPTINA PHOSPHATE TABLETS PACK : BOX3X10S | $52.1K | 2 |
| FOST DE SITAGLIPTINA TABLETS 100MG EACHTABLET CONTAINS: SITAGLIPTINA PHOSPHATETABLETS [10113 PACKS X3X10'S] BATCH NO | $50.0K | 1 |
| SITAGLIPTIN TABLETS 100MG 04X07S | $50.0K | 1 |
| SITAGLIPTIN SUN TABLETS 50MG, EACH FILMCOATED TABLET CONTAINS: SITAGLIPTIN FUMARATE EQUIVALENT TO 50 MG(PACK :4X7S) | $50.0K | 1 |
| FOST DE SITAGLIPTINA TABLETS 100MG (EACHTABLETS CONTAINS: SITAGLIPTINA PHOSPHATE TABLETS 100MG) [8370 PACKS X3X10'S] BA | $50.0K | 1 |
SUN Pharmaceutical Industries Limited exports 50 distinct Sitagliptin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FOST DE SITAGLIPTINA TAB 100MG 3X10B BREACH CONTAINS: SITAGL with 6 shipments worth $207.1K.
Regulatory Requirements: Exporting Sitagliptin to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Sitagliptin to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Sitagliptin Exporters?
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | FREDUN PHARMACEUTICALS LTD | $2.8M | 56 | 1 | $50.0K |
| 11 | BETA DRUGS LIMITED | $2.4M | 85 | 1 | $28.6K |
| 12 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $2.0M | 82 | 7 | $24.7K |
| 10 | BAFNA PHARMACEUTICALS LIMITED | $1.3M | 26 | 4 | $50.0K |
| 13 | DR REDDY S LABORATORIES LTD | $1.3M | 26 | 4 | $50.0K |
SUN Pharmaceutical Industries Limited ranks #12 among 309 Indian Sitagliptin exporters. Average shipment value of $24.7K compared to the market average of $149.3K. The closest competitors by value are FREDUN PHARMACEUTICALS LTD and BETA DRUGS LIMITED.
Which Indian Ports Ship Sitagliptin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 772 | 14.4% |
| DELHI AIR CARGO ACC (INDEL4) | 739 | 13.8% |
| SAHAR AIR | 735 | 13.7% |
| DELHI AIR | 513 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 217 | 4.0% |
| HYDERABAD AIR | 213 | 4.0% |
| Bombay Air | 196 | 3.7% |
| HYDERABAD ACC (INHYD4) | 191 | 3.6% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Sitagliptin Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Sitagliptin, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Sitagliptin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Sitagliptin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 82 individual customs records matching SUN Pharmaceutical Industries Limited exporting Sitagliptin, covering 50 formulations to 7 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 121+ countries, 575+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Sitagliptin Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Sitagliptin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Sitagliptin Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Sitagliptin. For current shipment-level data, contact TransData Nexus.